Table 2 Summary of Nottingham cohort

Number of patients

276

40

54

62

50

24

Age at diagnosis (years)

62.6 (10.7)

54.4 (16)

56.6 (17.8)

60.8 (11.8)

59.4 (12.2)

62 (12.2)

Overall survival (months)

34 (17 to 60)

80 (50 to 107.2)

63 (16 to 108)

90 (59 to 120)

52.5 (30.5 to 108.8)

44 (2 to 88.5)

Vital status

Data available

272 (99%)

38 (95%)

53 (98%)

61 (98%)

48 (96%)

23 (96%)

Alive

69 (25%)

30 (79%)

26 (49%)

36 (59%)

19 (40%)

11 (48%)

Died

203 (75%)

8 (21%)

27 (51%)

25 (41%)

29 (60%)

12 (52%)

Stage

Data available

270 (98%)

40 (100%)

52 (96%)

62 (100%)

48 (96%)

24 (100%)

I

41 (15%)

24 (60%)

42 (81%)

36 (58%)

28 (58%)

8 (33%)

II

31 (11%)

3 (8%)

1 (2%)

13 (21%)

8 (17%)

1 (4%)

III

168 (62%)

12 (30%)

7 (13%)

11 (18%)

12 (25%)

12 (50%)

IV

30 (11%)

1 (2%)

2 (4%)

2 (3%)

0 (0%)

3 (12%)

Grade

Data available

197 (71%)

21 (52%)

39 (72%)

60 (97%)

38 (76%)

10 (42%)

I

1 (1%)

20 (95%)

18 (46%)

10 (17%)

0 (0%)

2 (20%)

II

4 (2%)

0 (0%)

15 (38%)

17 (28%)

0 (0%)

1 (10%)

III

192 (97%)

1 (5%)

6 (15%)

33 (55%)

38 (100%)

7 (70%)

PTEN status (IHC)

Data available

233 (84%)

34 (85%)

40 (74%)

55 (89%)

43 (86%)

23 (96%)

Negative

27 (12%)

1 (3%)

4 (10%)

18 (33%)

14 (33%)

5 (22%)

Weak positive

65 (28%)

5 (15%)

17 (42%)

13 (24%)

17 (40%)

6 (26%)

Heterogeneous

29 (12%)

0 (0%)

3 (8%)

0 (0%)

1 (2%)

5 (22%)

Positive

112 (48%)

28 (82%)

16 (40%)

24 (44%)

11 (26%)

7 (30%)